Cita APA

Lopez-Huertas, M. R., Jiménez-Tormo, L., Madrid-Elena, N., Gutiérrez, C., Rodríguez-Mora, S., Coiras, M., . . . Moreno, S. (2017). The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.

Citación estilo Chicago

Lopez-Huertas, Maria Rosa, Laura Jiménez-Tormo, Nadia Madrid-Elena, Carolina Gutiérrez, Sara Rodríguez-Mora, Mayte Coiras, José Alcamí, y Santiago Moreno. The CCR5-antagonist Maraviroc Reverses HIV-1 Latency in Vitro Alone or in Combination With the PKC-agonist Bryostatin-1. 2017.

Cita MLA

Lopez-Huertas, Maria Rosa, et al. The CCR5-antagonist Maraviroc Reverses HIV-1 Latency in Vitro Alone or in Combination With the PKC-agonist Bryostatin-1. 2017.